{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:28:09Z","timestamp":1791041289033,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clml.2025.06.007","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T02:53:58Z","timestamp":1749696838000},"page":"e818-e825.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenstr\u00f6m\u2019s Macroglobulinemia"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-1229","authenticated-orcid":false,"given":"Maria","family":"Gavriatopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Spiliopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8971-269X","authenticated-orcid":false,"given":"Charalampos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Christine","family":"Kyrtsonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3482-4286","authenticated-orcid":false,"given":"Nikolaos","family":"Giannakoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Spanoudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sosanna","family":"Delimpasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michalis","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Giannouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Kaiafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Katodritou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.clml.2025.06.007_bib0001","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.007_bib0002","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-3-319-13150-4_7","article-title":"Biology, prognosis, and therapy of Waldenstr\u00f6m Macroglobulinemia","volume":"165","author":"Castillo","year":"2015","journal-title":"Cancer Treat Res"},{"issue":"25","key":"10.1016\/j.clml.2025.06.007_bib0003","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"iNNOVATE Study Group and the European Consortium for Waldenstr\u00f6m\u2019s Macroglobulinemia. Phase 3 trial of Ibrutinib plus Rituximab in Waldenstr\u00f6m's Macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.06.007_bib0004","article-title":"Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed\/refractory Waldenstrom macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial","author":"Benevolo","year":"2024","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.06.007_bib0005","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ajh.27543","article-title":"Autologous and allogeneic stem-cell transplantation for transformed Waldenstr\u00f6m macroglobulinemia","volume":"100","author":"Durot","year":"2025","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.007_bib0006","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ajh.27524","article-title":"First-line treatment of Waldenstr\u00f6m's macroglobulinemia in Italy: a multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies","volume":"100","author":"Autore","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.06.007_bib0007","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-024-06076-1","article-title":"on the behalf of the FILO group. Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed\/refractory patients with Waldenstr\u00f6m's macroglobulinemia","author":"Tomowiak","year":"2024","journal-title":"Ann Hematol"},{"issue":"14","key":"10.1016\/j.clml.2025.06.007_bib0008","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.22.01805","article-title":"Bortezomib-dexamethasone, rituximab, and cyclophosphamide as first-line treatment for Waldenstr\u00f6m's Macroglobulinemia: a prospectively randomized trial of the European Consortium for Waldenstr\u00f6m's Macroglobulinemia","volume":"41","author":"Buske","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.06.007_bib0009","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00277-018-3311-z","article-title":"Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstr\u00f6m macroglobulinemia","volume":"97","author":"Paludo","year":"2018","journal-title":"Ann Hematol"},{"issue":"33","key":"10.1016\/j.clml.2025.06.007_bib0010","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib versus Ibrutinib in symptomatic Waldenstr\u00f6m Macroglobulinemia: final analysis from the randomized phase III ASPEN study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.06.007_bib0011","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1111\/bjh.19409","article-title":"Long-term results of Waldenstr\u00f6m macroglobulinaemia treatment by bendamustine and rituximab: a study on behalf of the French Innovative Leukemia Organization (FILO)","volume":"204","author":"Laribi","year":"2024","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.clml.2025.06.007_bib0012","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1038\/s41375-019-0431-y","article-title":"A revised international prognostic score system for Waldenstr\u00f6m's macroglobulinemia","volume":"33","author":"Kastritis","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2025.06.007_bib0013","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.chest.2023.08.004","article-title":"7.4-Year-old man with Waldenstr\u00f6m macroglobulinemia and progressive dyspnea","volume":"165","author":"Tzilas","year":"2024","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.clml.2025.06.007_bib0014","doi-asserted-by":"crossref","first-page":"77","DOI":"10.21873\/cdp.10289","article-title":"Long-term survival in a patient with transformation of Waldenstr\u00f6m's macroglobulinemia into DLBCL","volume":"4","author":"Solia","year":"2024","journal-title":"Cancer Diagn Progn"},{"issue":"21","key":"10.1016\/j.clml.2025.06.007_bib0015","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.23.02066","article-title":"Simplified risk stratification model for patients with Waldenstr\u00f6m macroglobulinemia","volume":"42","author":"Zanwar","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.06.007_bib0016","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.3324\/haematol.2020.262899","article-title":"A prognostic index predicting survival in transformed Waldenstr\u00f6m macroglobulinemia","volume":"106","author":"Durot","year":"2021","journal-title":"Haematologica"},{"issue":"44","key":"10.1016\/j.clml.2025.06.007_bib0017","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017794","article-title":"Treatment of Bing-Neel syndrome with first line sequential chemoimmunotherapy: a case report","volume":"98","author":"Gavriatopoulou","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"25","key":"10.1016\/j.clml.2025.06.007_bib0018","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1182\/blood-2014-05-574871","article-title":"Survival trends in Waldenstr\u00f6m macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database","volume":"123","author":"Castillo","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.06.007_bib0019","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3816\/CLML.2011.n.016","article-title":"Associated malignancies in patients with Waldenstr\u00f6m's macroglobulinemia and their kin","volume":"11","author":"Hanzis","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.clml.2025.06.007_bib0020","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1200\/JCO.2007.15.1530","article-title":"Increased incidence of transformation and myelodysplasia\/acute leukemia in patients with Waldenstr\u00f6m macroglobulinemia treated with nucleoside analogs","volume":"27","author":"Leleu","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3\u20134","key":"10.1016\/j.clml.2025.06.007_bib0021","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/10428199909050950","article-title":"High-grade transformation of low-grade non-hodgkin's lymphomas: mechanisms of tumor progression","volume":"34","author":"Matolcsy","year":"1999","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2025.06.007_bib0022","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/sonc.2003.50069","article-title":"Developing diagnostic criteria in Waldenstrom's macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.06.007_bib0023","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ajh.26796","article-title":"Waldenstr\u00f6m macroglobulinemia: 2023 update on diagnosis, risk stratification, and management","volume":"98","author":"Gertz","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.007_bib0024","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/bjh.13264","article-title":"Overall survival and competing risks of death in patients with Waldenstr\u00f6m macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database","volume":"169","author":"Castillo","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.007_bib0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-023-00784-z","article-title":"Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019","volume":"13","author":"van der Straten","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2025.06.007_bib0026","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1002\/cam4.5139","article-title":"Secondary malignancies in non-Hodgkin lymphoma survivors: 40\u2009years of follow-up assessed by treatment modality","volume":"12","author":"Parsons","year":"2023","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.clml.2025.06.007_bib0027","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/annonc\/mdr537","article-title":"Second malignancies among Waldenstrom macroglobulinemia patients: small samples and sparse data","volume":"23","author":"Ojha","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.06.007_sbref0028","series-title":"Holland-Frei cancer medicine","article-title":"Secondary cancers: incidence, risk factors, and management","author":"Rheingold","year":"2003"},{"issue":"3","key":"10.1016\/j.clml.2025.06.007_bib0029","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.2012.44.7920","article-title":"Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstr\u00f6m macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma","volume":"31","author":"Leblond","year":"2013","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.clml.2025.06.007_bib0030","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.3390\/cancers15174359","article-title":"Outcome of second primary malignancies developing in Multiple Myeloma patients","volume":"15","author":"Avivi","year":"2023","journal-title":"Cancers (Basel)."},{"issue":"12","key":"10.1016\/j.clml.2025.06.007_bib0031","doi-asserted-by":"crossref","first-page":"e906","DOI":"10.1016\/S2352-3026(22)00289-7","article-title":"Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Saleem","year":"2022","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.06.007_bib0032","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Palumbo A; International Myeloma Working Group. Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann Oncol."},{"issue":"3","key":"10.1016\/j.clml.2025.06.007_bib0033","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ajh.25697","article-title":"Impact of MYD88L265P mutation status on histological transformation of Waldenstr\u00f6m Macroglobulinemia","volume":"95","author":"Zanwar","year":"2020","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.clml.2025.06.007_bib0034","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/annonc\/mdr119","article-title":"Risk of second cancers in Waldenstr\u00f6m macroglobulinemia","volume":"23","author":"Varettoni","year":"2012","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.06.007_bib0035","first-page":"645","article-title":"Second primary malignancies in Waldenstrom's macroglobulinemia: a US population-based study","volume":"26","author":"Giri","year":"2015","journal-title":"Cancer Causes Control"},{"issue":"15","key":"10.1016\/j.clml.2025.06.007_bib0036","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1158\/1538-7445.AM2015-3709","article-title":"Abstract 3709: second cancers following Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma in the United States: analysis of Surveillance, Epidemiology and End Results (SEER) registry data, 1992 - 2011","volume":"75","author":"McMaster","year":"2015","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.clml.2025.06.007_bib0037","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/cncr.29334","article-title":"Incidence of secondary malignancies among patients with Waldenstr\u00f6m macroglobulinemia: an analysis of the SEER database","volume":"121","author":"Castillo","year":"2015","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.clml.2025.06.007_bib0038","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1002\/cncr.30164","article-title":"Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008","volume":"122","author":"Donin","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2025.06.007_bib0039","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S1470-2045(23)00538-7","article-title":"Cumulative incidence of second primary cancers in a large nationwide cohort of Danish cancer survivors: a population-based retrospective cohort study","volume":"25","author":"Kjaer","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:06:50Z","timestamp":1758604010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2152265025002137"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenstr\u00f6m\u2019s Macroglobulinemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}